Archives
GSK621: Potent AMPK Agonist for Metabolic and AML Research
GSK621: Potent AMPK Agonist for Metabolic and AML Research
Executive Summary: GSK621 is a selective AMP-activated protein kinase (AMPK) agonist validated for precise metabolic pathway interrogation in cell and animal models (APExBIO). It induces AMPK activation via phosphorylation at AMPKα T172, inhibits mTORC1 signaling, and promotes autophagy and apoptosis in acute myeloid leukemia (AML) cells (Xiao et al., 2024). GSK621 outperforms legacy agonists such as A-769662 in activating AMPK substrates ULK1 (S555) and ACC (S79) in AML systems (see benchmark). In vivo, intraperitoneal administration at 30 mg/kg twice daily reduces leukemia burden and extends survival in MOLM-14 xenograft mice. The compound is insoluble in water/ethanol but dissolves in DMSO at ≥28.5 mg/mL, enabling high-concentration stock solutions for experimental flexibility (product sheet).
Biological Rationale
AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine kinase that functions as a central metabolic sensor. AMPK regulates energy homeostasis by responding to cellular AMP/ATP ratios. Activation of AMPK leads to downstream inhibition of anabolic pathways, such as fatty acid and protein biosynthesis, and stimulation of catabolic processes, including autophagy and fatty acid oxidation (Xiao et al., 2024). Dysregulation of AMPK signaling is implicated in malignancies such as acute myeloid leukemia (AML), where metabolic plasticity contributes to tumor progression and immune evasion.
Recent studies have linked AMPK activity to immune cell function. In tumor-associated macrophages (TAMs), cholesterol-derived metabolites such as 25-hydroxycholesterol (25HC) can modulate AMPK via lysosomal accumulation, impacting STAT6 activation and macrophage immunosuppressive phenotype. Targeted modulation of AMPK offers both metabolic and immunological research opportunities (Xiao et al., 2024).
Mechanism of Action of GSK621
GSK621 (6-chloro-5-(2'-hydroxy-3'-methoxy-[1,1'-biphenyl]-4-yl)-3-(3-methoxyphenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione) is a synthetic, crystalline solid AMPK agonist with a molecular weight of 489.91 g/mol (APExBIO). It selectively binds and activates AMPK by increasing phosphorylation at AMPKα T172, a modification essential for kinase activation. This activation leads to downstream phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) at S79, suppressing fatty acid biosynthesis. GSK621 also activates ULK1 via S555 phosphorylation, promoting autophagy initiation (detail here).
GSK621’s effects extend to inhibition of mTORC1-dependent protein synthesis, a key regulator of cell growth and proliferation. This dual modulation—AMPK activation and mTORC1 inhibition—results in reduced glucose anabolism, enhanced fatty acid oxidation, and increased apoptotic signaling in AML cells (Xiao et al., 2024).
Evidence & Benchmarks
- GSK621 activates AMPK by increasing phosphorylation at AMPKα T172 in both AML cell lines and primary AML samples (DOI).
- Phosphorylation of AMPK substrates ULK1 (S555) and ACC (S79) is more robust with GSK621 than with A-769662 in AML models (source).
- In vivo, GSK621 at 30 mg/kg (i.p., twice daily) significantly reduces leukemia burden and increases survival in MOLM-14 xenograft mice (DOI).
- GSK621 inhibits mTORC1 signaling, as shown by decreased p-S6K in treated cells (figure 4B).
- GSK621 induces apoptosis in AML cells, correlating with increased AMPK activity and decreased cell proliferation (refined protocol).
- Compound is insoluble in water/ethanol but dissolves in DMSO at ≥28.5 mg/mL; optimal solubility achieved by warming at 37°C or ultrasonic bath (APExBIO).
Applications, Limits & Misconceptions
GSK621 is intended exclusively for scientific research in metabolic pathway modulation, cancer cell metabolism, and immunometabolic signaling. It is not for diagnostic or therapeutic use in humans or animals (APExBIO).
Common Pitfalls or Misconceptions
- GSK621 is not effective in models lacking functional AMPK complexes (e.g., AMPKα knockout cells).
- Compound is not soluble in aqueous buffers or ethanol—use DMSO for stock solutions.
- Not validated for chronic in vivo dosing beyond acute AML xenograft models.
- Not suitable for diagnostic procedures or direct clinical application.
- Over-interpretation of AMPK-independent effects should be avoided; parallel controls with AMPK inhibitors are recommended.
This article extends the depth of 'GSK621: Unlocking AMPK Signaling for Immunometabolic & AML Research' by focusing on quantitative in vivo benchmarks and solubility optimization, while 'GSK621: Cell-Permeable AMPK Agonist for Precision Metabolic Research' covers mechanistic and protocol nuances for cell-based studies.
Workflow Integration & Parameters
GSK621 (SKU B6020) is supplied as a crystalline solid by APExBIO. Reconstitute in DMSO to ≥28.5 mg/mL; warm at 37°C or use an ultrasonic bath for optimal dissolution. Store stock solutions below -20°C for several months; solid compound is stable at 2–8°C (APExBIO).
For in vitro studies, titrate concentrations based on cell line sensitivity (typically 1–10 μM). For in vivo use, administer via intraperitoneal injection at validated doses (e.g., 30 mg/kg, twice daily for AML xenografts). Always include vehicle and pathway-specific controls. Where possible, confirm AMPK pathway engagement by immunoblotting for p-AMPKα (T172), p-ULK1 (S555), and p-ACC (S79) (see protocol guidance).
Conclusion & Outlook
GSK621 is a validated, potent AMPK agonist for metabolic and oncology research. Its high specificity, robust in vivo efficacy, and defined solubility make it a cornerstone in AMPK pathway interrogation, particularly in AML and immunometabolic studies. The compound's ability to modulate both metabolic and immune cell signaling supports its use in multi-parametric research workflows. For additional mechanistic insight or protocol troubleshooting, refer to related content and product documentation. Continued benchmarking in diverse cell systems and emerging immunometabolic paradigms is warranted.